Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2019-03-15 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于获得“nanatinostat”独家许可使用权暨子公司对外投资的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acquisition of exclusive licensing rights for 'nanatinostat' and the progress of a subsidiary's external investment. It details the company's board meeting resolution, the subsidiary's investment in a US company (Viracta Therapeutics, Inc.), and the shareholding percentage acquired. The document is short (806 characters) and focuses on investment and capital structure changes related to share subscription and ownership percentage. There is no financial report, earnings data, or regulatory certification. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-03-15 Chinese
关于举行2018年年度报告网上说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about holding an online explanation meeting for the 2018 annual report. It specifies the date and time of the meeting and how investors can participate. It does not contain the actual annual report or detailed financial data, but rather invites investors to a presentation or discussion about the annual report. The document length is short (613 characters), and it is clearly an announcement of a meeting related to the annual report, not the report itself. Therefore, it fits best under the category of Investor Presentation (IP), as it is a detailed presentation event for investors focusing on financials and company performance.
2019-03-13 Chinese
关于公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled "专项审核报告" (Special Audit Report) concerning non-operating fund occupation and other related party fund transactions for Shenzhen Salubris Pharmaceuticals Co., Ltd. It references the 2018 fiscal year and includes an audit opinion by a registered accounting firm. The content focuses on auditing a specific financial summary table related to related-party transactions, not a full annual report or interim financial statements. The document length is 3699 characters, which is relatively short but contains an audit opinion and detailed financial data related to the audit scope. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. Therefore, the document should be classified as AR with high confidence. FY 2018
2019-03-11 Chinese
独立董事关于公司有关事项所发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various company matters including profit distribution plan, appointment of deputy general manager, remuneration, audit firm reappointment, internal control self-assessment, accounting policy changes, use of idle funds, guarantees for subsidiaries, amendments to company articles, and external guarantees and related party fund occupation. It references the 2018 fiscal year and includes detailed opinions on governance, compliance, and internal controls. The document is not a full annual report or audit report but rather a formal independent directors' statement on company governance and related matters. It is not a short announcement or certification but a substantive governance-related opinion document. This fits best under Board/Management Information (MANG) as it relates to board opinions on management and governance matters, including appointments and remuneration. The document length is under 5,000 characters but contains detailed independent opinions rather than a simple announcement, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2019-03-11 Chinese
股东大会议事规则（2019年3月）
Governance Information Classification · 100% confidence The document is titled '股东大会议事规则' which translates to 'Rules of Procedure for the Shareholders' General Meeting'. It details the procedures, rights, and regulations governing the conduct of shareholders' meetings, including annual and extraordinary meetings, voting procedures, proposal submissions, and legal compliance. It does not contain financial statements, audit results, or earnings data. It is a governance document outlining internal rules and processes related to shareholder meetings. Therefore, it fits the category of Governance Information (CGR). The document length is over 10,000 characters, indicating it is a full set of rules, not just an announcement or summary.
2019-03-11 Chinese
《公司章程》修正案
Governance Information Classification · 95% confidence The document is a detailed amendment to the company's Articles of Association (公司章程), including changes to provisions about share repurchases, shareholder meeting powers, board responsibilities, and profit distribution policies. It references compliance with laws and stock exchange rules, and it is intended for submission to the 2018 Annual General Meeting for approval. The content is about governance structure and internal rules rather than financial results or announcements. It is not a report of financial performance, audit, or earnings, nor is it a voting result announcement or a proxy statement. The document is a governance-related filing detailing the company's internal rules and governance practices.
2019-03-11 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.